<DOC>
	<DOCNO>NCT01019876</DOCNO>
	<brief_summary>Reduced intensity conditioning follow allogeneic stem cell transplantation result mixed/complete donor chimerism potentially alter natural history outcome patient non-malignant disease .</brief_summary>
	<brief_title>Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases</brief_title>
	<detailed_description>This study determine toxicity administer fludarabine/cyclophosphamide ( Flu/CY ) busulfan ( Bu ) /Flu base condition regimen follow allogeneic stem cell transplant ( AlloSCT ) patient non-malignant disease .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Osteopetrosis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Inclusion Criteria Patients must meet eligibility criterion organ function regardless diagnosis : Age &lt; 30 = 30 year age Adequate renal function define serum creatinine &lt; = 1.5 x normal , creatinine clearance radioisotope GFR &gt; =40 ml/min/m2 &gt; 60 ml/min/1.73 m2 equivalent GFR determine institutional normal range Adequate liver function define SGOT ( AST ) SGPT ( ALT ) &lt; 5.0 x normal Adequate cardiac function define shorten fraction &gt; = 28 % echocardiogram , ejection fraction &gt; = 48 % radionuclide angiogram echocardiogram Adequate pulmonary function define asymptomatic , symptomatic , DLCO &gt; 45 % predict ( correct hemoglobin level ) . If unable obtain pulmonary function test , O2 saturation &gt; 85 % room air . Bone Marrow Failure Syndromes Patients follow diagnosis eligible : Severe Aplastic Anemia : Hypocellular bone marrow biopsy ( &lt; 25 % cellularity ) 2/3 follow ( diagnosis nadir ) : Absolute Neutrophil Count ( ANC ) &lt; 200/mm3 , Platelets &lt; 20,000/mm3 Reticulocyte count &lt; 60,000/mm3 Fanconi Anemia : Abnormal clastogenic study ( patient ) Severe Congenital Neutropenia ( Kostmann 's Syndrome ) Amegakaryocytic Thrombocytopenia Severe thrombocytopenia ( &lt; =20,000/mm3 ) diagnosis Severe depletion megakaryocytes bone marrow aspirate ( &lt; =25 % normal ) DiamondBlackfan Anemia : Corticosteroid dependent &gt; 6 month OR Transfusion dependent OR refractory acquire pure red cell aplasia . Infantile Osteopetrosis SchwachmanDiamond Syndrome Dyskeratosis Congenita Other bone marrow failure syndromes discretion coprincipal investigator Immunodeficiencies SCIDS , subtypes Combined Immunodeficiency Syndrome WiskottAldrich Syndrome Chronic Granulomatous Disease ChediakHigashi Syndrome Leukocyte Adhesion Deficiency Other immunodeficiency discretion coprincipal investigator Inborn Errors Metabolism ( IEOM ) Transplant recommend follow disorder : Hurler syndrome ( alphaLiduronidase deficiency , MPSI ) , preferably age 24 month MaroteauxLamy syndrome ( galactosamine4sulfatase deficiency , MPSVI ) Sly syndrome ( betaglucuronidase deficiency , MPSVII ) Globoid cell leukodystrophy ( galactocerebrosidase deficiency ) , careful attention neurologic status infantile form Metachromatic leukodystrophy ( arylsulfatase A deficiency ) , juvenile adult onset form ; late infantile MLD presymptomatic Childhoodonset Xlinked adrenoleukodystrophy ( XALD ) , initial sign neuropsychological deterioration , dietary modification prior transplant Fucosidosis ( fucosidase deficiency ) Mannosidosis Aspartylglucosaminuria NiemannPick Disease Type B ( acid sphingomyelinase deficiency ) Other diagnosis may consider discretion coprincipal investigator For XALD patient great 5 year age , IQ &gt; 80 require . For patient great 5 year age , IQ &gt; 70 require . For Gaucher disease ( glucocerebrosidase deficiency ) Type I ( nonneuropathic ) , primary therapy enzyme replacement , allogeneic stem cell transplant use effectively . Histiocytoses Hemophagocytic Lymphohistiocytosis ( HLH ) Familial Erythrophagocytic Lymphohistiocytosis Langerhans Cell Histiocytosis Patients multisystem disease whose initial disease stable progressive minimum 6 week appropriate therapy , OR Patients recurrent multisystem disease . Malignant Histiocytosis Other nonmalignant disease list may eligible deemed appropriate coprincipal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Bone marrow Failure</keyword>
	<keyword>Fanconi</keyword>
	<keyword>SCID</keyword>
</DOC>